Compare Amphastar Pharmaceuticals Inc (AMPH) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Expensify Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Expensify Inc trades at $2.27 (market cap $224.32M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 3.9× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | EXFY | |
|---|---|---|
Market Cap | $863.95M | $224.32M |
Sector | Health | Technology |
52-Week High | $30.81 | $2.69 |
52-Week Low | $16.87 | $0.75 |
Enterprise Value | $1.26B | $163.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Expensify (EXFY) trades at $2.69, up 35.86% in 24 hours, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. Despite negative net margins, cash flow from operations improved to $20.09 million in 2025, and the balance sheet shows $48.77 million in cash with low debt.
The outlook is cautiously optimistic due to earnings beats and AI-driven growth initiatives, but high P/E of 258.82 and persistent losses pose valuation risks. Analyst consensus is split between Buy and Hold, reflecting uncertainty over profitability sustainability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
